Fady Ibraham Malik's most recent trade in Cytokinetics Inc was a trade of 2,000 Common Stock done . Disclosure was reported to the exchange on Dec. 22, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Dec 2025 | 2,000 | 140,552 (0%) | 0% | 0 | Common Stock | |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Dec 2025 | 2,000 | 142,552 (0%) | 0% | 0 | Common Stock | |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 62.72 per share. | 22 Dec 2025 | 1,016 | 141,536 (0%) | 0% | 62.7 | 63,724 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.60 per share. | 16 Dec 2025 | 2,200 | 140,752 (0%) | 0% | 10.6 | 23,320 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Dec 2025 | 2,200 | 0 | - | - | Incentive Stock Option (Right to Buy) | |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Sale of securities on an exchange or to another person at price $ 61.24 per share. | 16 Dec 2025 | 2,200 | 138,552 (0%) | 0% | 61.2 | 134,728 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 65.02 per share. | 03 Dec 2025 | 2,058 | 138,552 (0%) | 0% | 65.0 | 133,811 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.60 per share. | 02 Dec 2025 | 2,200 | 142,810 (0%) | 0% | 10.6 | 23,320 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Dec 2025 | 2,200 | 2,200 | - | - | Incentive Stock Option (Right to Buy) | |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Sale of securities on an exchange or to another person at price $ 63.89 per share. | 02 Dec 2025 | 2,200 | 140,610 (0%) | 0% | 63.9 | 140,558 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Nov 2025 | 2,200 | 4,400 | - | - | Incentive Stock Option (Right to Buy) | |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Sale of securities on an exchange or to another person at price $ 66.45 per share. | 18 Nov 2025 | 2,200 | 140,610 (0%) | 0% | 66.5 | 146,190 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.60 per share. | 18 Nov 2025 | 2,200 | 142,810 (0%) | 0% | 10.6 | 23,320 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Nov 2025 | 2,295 | 6,600 | - | - | Incentive Stock Option (Right to Buy) | |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Sale of securities on an exchange or to another person at price $ 59.55 per share. | 04 Nov 2025 | 2,295 | 140,610 (0%) | 0% | 59.5 | 136,667 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.60 per share. | 04 Nov 2025 | 2,295 | 142,905 (0%) | 0% | 10.6 | 24,327 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Sale of securities on an exchange or to another person at price $ 58.22 per share. | 21 Oct 2025 | 2,105 | 140,610 (0%) | 0% | 58.2 | 122,553 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.60 per share. | 21 Oct 2025 | 2,105 | 142,715 (0%) | 0% | 10.6 | 22,313 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Oct 2025 | 2,105 | 1,000 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Oct 2025 | 2,000 | 3,105 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Sale of securities on an exchange or to another person at price $ 60.56 per share. | 07 Oct 2025 | 2,000 | 140,610 (0%) | 0% | 60.6 | 121,120 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.60 per share. | 07 Oct 2025 | 2,000 | 142,610 (0%) | 0% | 10.6 | 21,200 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.60 per share. | 23 Sep 2025 | 2,000 | 142,610 (0%) | 0% | 10.6 | 21,200 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Sep 2025 | 2,000 | 5,105 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Sale of securities on an exchange or to another person at price $ 49.28 per share. | 23 Sep 2025 | 2,000 | 140,610 (0%) | 0% | 49.3 | 98,560 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Sep 2025 | 2,000 | 7,105 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Sale of securities on an exchange or to another person at price $ 51.29 per share. | 09 Sep 2025 | 2,000 | 140,610 (0%) | 0% | 51.3 | 102,580 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.60 per share. | 09 Sep 2025 | 2,000 | 142,610 (0%) | 0% | 10.6 | 21,200 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.60 per share. | 19 Aug 2025 | 2,000 | 142,610 (0%) | 0% | 10.6 | 21,200 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Aug 2025 | 2,000 | 9,105 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Sale of securities on an exchange or to another person at price $ 38.31 per share. | 19 Aug 2025 | 2,000 | 140,610 (0%) | 0% | 38.3 | 76,620 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Aug 2025 | 2,000 | 11,105 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Sale of securities on an exchange or to another person at price $ 36.34 per share. | 05 Aug 2025 | 2,000 | 140,610 (0%) | 0% | 36.3 | 72,680 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.60 per share. | 05 Aug 2025 | 2,000 | 142,610 (0%) | 0% | 10.6 | 21,200 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jul 2025 | 2,000 | 13,105 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Sale of securities on an exchange or to another person at price $ 37.47 per share. | 22 Jul 2025 | 2,000 | 140,610 (0%) | 0% | 37.5 | 74,940 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.60 per share. | 22 Jul 2025 | 2,000 | 142,610 (0%) | 0% | 10.6 | 21,200 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jul 2025 | 2,000 | 15,105 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Sale of securities on an exchange or to another person at price $ 33.76 per share. | 08 Jul 2025 | 2,000 | 140,610 (0%) | 0% | 33.8 | 67,520 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.60 per share. | 08 Jul 2025 | 2,000 | 142,610 (0%) | 0% | 10.6 | 21,200 | Common Stock |
| Rocket Pharmaceuticals Inc | Fady Ibraham Malik | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2025 | 30,000 | 30,000 (0%) | 0% | 0 | Common Stock | |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jun 2025 | 2,000 | 17,105 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Sale of securities on an exchange or to another person at price $ 32.91 per share. | 17 Jun 2025 | 2,000 | 140,610 (0%) | 0% | 32.9 | 65,820 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.60 per share. | 17 Jun 2025 | 2,000 | 142,610 (0%) | 0% | 10.6 | 21,200 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.60 per share. | 03 Jun 2025 | 2,000 | 142,610 (0%) | 0% | 10.6 | 21,200 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jun 2025 | 2,000 | 19,105 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Sale of securities on an exchange or to another person at price $ 31.88 per share. | 03 Jun 2025 | 2,000 | 140,610 (0%) | 0% | 31.9 | 63,760 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.60 per share. | 20 May 2025 | 2,000 | 142,255 (0%) | 0% | 10.6 | 21,200 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Sale of securities on an exchange or to another person at price $ 31.98 per share. | 20 May 2025 | 2,000 | 140,255 (0%) | 0% | 32.0 | 63,960 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 May 2025 | 2,000 | 21,105 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Sale of securities on an exchange or to another person at price $ 35.01 per share. | 06 May 2025 | 2,000 | 140,255 (0%) | 0% | 35.0 | 70,020 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 May 2025 | 2,000 | 23,105 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.60 per share. | 06 May 2025 | 2,000 | 142,255 (0%) | 0% | 10.6 | 21,200 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Apr 2025 | 2,000 | 25,105 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Sale of securities on an exchange or to another person at price $ 38.11 per share. | 22 Apr 2025 | 2,000 | 140,255 (0%) | 0% | 38.1 | 76,220 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.60 per share. | 22 Apr 2025 | 2,000 | 142,255 (0%) | 0% | 10.6 | 21,200 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Apr 2025 | 2,000 | 27,105 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Sale of securities on an exchange or to another person at price $ 36.18 per share. | 08 Apr 2025 | 2,000 | 140,255 (0%) | 0% | 36.2 | 72,360 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.60 per share. | 08 Apr 2025 | 2,000 | 142,255 (0%) | 0% | 10.6 | 21,200 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Gift of securities by or to the insider at price $ 0.00 per share. | 19 Mar 2025 | 200 | 140,255 (0%) | 0% | 0 | Common Stock | |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Mar 2025 | 2,000 | 29,105 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.60 per share. | 18 Mar 2025 | 2,000 | 142,455 (0%) | 0% | 10.6 | 21,200 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Sale of securities on an exchange or to another person at price $ 43.58 per share. | 18 Mar 2025 | 2,000 | 140,455 (0%) | 0% | 43.6 | 87,160 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Sale of securities on an exchange or to another person at price $ 44.38 per share. | 17 Mar 2025 | 4,389 | 101,005 (0%) | 0% | 44.4 | 194,784 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2025 | 58,465 | 58,465 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2025 | 39,450 | 144,844 (0%) | 0% | 0 | Common Stock | |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2025 | 2,293 | 2,293 | - | - | Incentive Stock Option (Right to Buy) | |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Sale of securities on an exchange or to another person at price $ 43.27 per share. | 06 Mar 2025 | 8,228 | 105,394 (0%) | 0% | 43.3 | 356,026 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2025 | 2,000 | 31,105 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Sale of securities on an exchange or to another person at price $ 42.50 per share. | 04 Mar 2025 | 2,000 | 116,071 (0%) | 0% | 42.5 | 85,000 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.60 per share. | 04 Mar 2025 | 2,000 | 118,071 (0%) | 0% | 10.6 | 21,200 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Sale of securities on an exchange or to another person at price $ 42.88 per share. | 03 Mar 2025 | 2,449 | 113,622 (0%) | 0% | 42.9 | 105,013 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.60 per share. | 18 Feb 2025 | 2,000 | 118,071 (0%) | 0% | 10.6 | 21,200 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Sale of securities on an exchange or to another person at price $ 45.98 per share. | 18 Feb 2025 | 2,000 | 116,071 (0%) | 0% | 46.0 | 91,960 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2025 | 2,000 | 33,105 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.60 per share. | 04 Feb 2025 | 2,000 | 118,071 (0%) | 0% | 10.6 | 21,200 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Feb 2025 | 2,000 | 35,105 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Sale of securities on an exchange or to another person at price $ 48.06 per share. | 04 Feb 2025 | 2,000 | 116,071 (0%) | 0% | 48.1 | 96,120 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.60 per share. | 21 Jan 2025 | 2,000 | 118,071 (0%) | 0% | 10.6 | 21,200 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Jan 2025 | 2,000 | 37,105 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Sale of securities on an exchange or to another person at price $ 45.92 per share. | 21 Jan 2025 | 2,000 | 116,071 (0%) | 0% | 45.9 | 91,840 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.96 per share. | 10 Dec 2024 | 5,300 | 123,371 (0%) | 0% | 8.0 | 42,188 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Dec 2024 | 5,300 | 0 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Sale of securities on an exchange or to another person at price $ 50.63 per share. | 10 Dec 2024 | 5,300 | 118,071 (0%) | 0% | 50.6 | 268,339 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Sale of securities on an exchange or to another person at price $ 50.65 per share. | 10 Dec 2024 | 2,000 | 116,071 (0%) | 0% | 50.7 | 101,300 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Dec 2024 | 4,000 | 118,071 (0%) | 0% | 0 | Common Stock | |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Dec 2024 | 4,000 | 116,099 (0%) | 0% | 0 | Common Stock | |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 51.51 per share. | 03 Dec 2024 | 2,028 | 114,071 (0%) | 0% | 51.5 | 104,462 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Sale of securities on an exchange or to another person at price $ 50.17 per share. | 26 Nov 2024 | 5,300 | 113,878 (0%) | 0% | 50.2 | 265,901 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Nov 2024 | 5,300 | 5,300 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.96 per share. | 26 Nov 2024 | 5,300 | 119,178 (0%) | 0% | 8.0 | 42,188 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Sale of securities on an exchange or to another person at price $ 50.14 per share. | 26 Nov 2024 | 2,000 | 111,878 (0%) | 0% | 50.1 | 100,280 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Nov 2024 | 5,300 | 10,600 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Sale of securities on an exchange or to another person at price $ 58.48 per share. | 12 Nov 2024 | 5,300 | 114,920 (0%) | 0% | 58.5 | 309,944 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.96 per share. | 12 Nov 2024 | 5,300 | 120,220 (0%) | 0% | 8.0 | 42,188 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Sale of securities on an exchange or to another person at price $ 58.48 per share. | 12 Nov 2024 | 1,042 | 113,878 (0%) | 0% | 58.5 | 60,936 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Sale of securities on an exchange or to another person at price $ 51.90 per share. | 30 Oct 2024 | 5,300 | 116,920 (0%) | 0% | 51.9 | 275,070 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Oct 2024 | 5,300 | 15,900 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.96 per share. | 30 Oct 2024 | 5,300 | 122,220 (0%) | 0% | 8.0 | 42,188 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Sale of securities on an exchange or to another person at price $ 51.93 per share. | 30 Oct 2024 | 2,000 | 114,920 (0%) | 0% | 51.9 | 103,860 | Common Stock |
| Cytokinetics Inc | Fady Ibraham Malik | EVP Research & Development | Sale of securities on an exchange or to another person at price $ 54.18 per share. | 15 Oct 2024 | 5,300 | 118,920 (0%) | 0% | 54.2 | 287,154 | Common Stock |